Olema Pharmaceuticals, Inc. Stock Price, News & Analysis

Olema Oncology (NASDAQ: OLMA) has announced the selection of 90 mg once-daily palazestrant dose for two pivotal Phase 3 trials: OPERA-01 and OPERA-02. The FDA-aligned dose selection applies to Part 2 of OPERA-01, a monotherapy trial for second- and third-line ER+/HER2- metastatic breast cancer, and OPERA-02, which combines palazestrant with ribociclib for frontline treatment. The company will present a trial-in-progress poster for OPERA-01 at the upcoming ASCO 2025 Annual Meeting in Chicago. Olema expects to report top-line data from OPERA-01 in 2026 with a potential commercial launch in 2027. The development targets resistance mechanisms in metastatic breast cancer treatment, with palazestrant showing promising results across ESR1 mutant and wild-type ER+/HER2- tumors in both monotherapy and combination settings.

Olema Pharmaceuticals (Nasdaq: OLMA), a clinical-stage biopharmaceutical company specializing in targeted therapies for breast cancer, has announced its participation in two upcoming investor conferences. The company will present at the Jefferies Global Healthcare Conference on June 4, 2025, at 11:40 a.m. ET in New York, and the Goldman Sachs 46th Annual Global Healthcare Conference on June 11, 2025, at 8 a.m. ET in Miami. Both presentations will be in a fireside chat format. Live webcasts and recordings will be accessible through Olema's investor relations website at ir.olema.com.

Olema Oncology reported its Q1 2025 financial results and operational progress. The company ended Q1 with $392.7 million in cash and a net loss of $30.4 million. Key developments include:

The company's lead drug palazestrant showed promising results in Phase 1b/2 study, achieving 13.8 months median progression-free survival in combination with ribociclib for ER+/HER2- metastatic breast cancer patients. Two pivotal Phase 3 trials are advancing: OPERA-01 (monotherapy) with top-line data expected in 2026, and OPERA-02 (combination therapy) set to begin in 2025.

Additionally, Olema presented preclinical data for OP-3136, demonstrating anti-tumor activity in ovarian, non-small cell lung, and prostate cancer models. The Phase 1 trial for OP-3136 continues patient enrollment.

Olema Pharmaceuticals (NASDAQ: OLMA), a clinical-stage biopharmaceutical company specializing in targeted therapies for breast cancer, has announced its participation in two upcoming investor conferences. The company will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, at 4:30 p.m. ET in New York, and the T.D. Cowen 6th Annual Oncology Innovation Summit on May 27, 2025, at 5 p.m. ET in a virtual format. Both presentations will be in a fireside chat format. Live webcasts and recordings will be accessible through Olema's investor relations website at ir.olema.com.

Olema Pharmaceuticals (NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer, has granted stock options to four new employees. The grants total 104,400 shares of common stock with an exercise price of $5.29 per share, matching the company's last reported sale price on May 1, 2025.

The stock options, approved under Olema's 2022 Inducement Plan, will vest over four years, with 25% vesting on the first anniversary and the remaining portion vesting in 36 monthly installments. The options have a 10-year term and are contingent on continuous employment.

Olema Oncology (OLMA) has revealed promising preclinical data for OP-3136, their novel KAT6 inhibitor, demonstrating significant anti-tumor activity across multiple solid tumor types. The data, presented at AACR 2025, showed effectiveness in ovarian, prostate, and non-small cell lung cancer (NSCLC) models.

Key findings include potent anti-proliferative activity in various cell lines and notable results in xenograft models:

• OVCAR3 (ovarian) model showed sustained tumor regression over 28 days
• LCLC-97TM1 (NSCLC) model demonstrated tumor inhibition comparable to ribociclib
• 22Rv1 (prostate) model exhibited dose-dependent tumor growth inhibition

The company is currently recruiting patients for a Phase 1 trial of OP-3136 as both monotherapy and in combination regimens for multiple solid tumor types.

Olema Pharmaceuticals (Nasdaq: OLMA) has announced the granting of stock options to 5 new employees as part of their inducement awards. The options allow the purchase of 64,900 shares of common stock at an exercise price of $3.34 per share, matching the company's last reported sale price on April 1, 2025.

The stock options, approved by Olema's Compensation Committee under the 2022 Inducement Plan, feature a four-year vesting schedule: 25% vests on the first anniversary, followed by 36 monthly installments over three years, contingent on continuous employment. The options have a 10-year term and comply with Nasdaq Listing Rule 5635(c)(4).

Olema Oncology (Nasdaq: OLMA) has announced upcoming presentation of preclinical data for OP-3136, their novel KAT6 inhibitor, at the 2025 AACR Annual Meeting in Chicago. The presentation will showcase the drug's anti-tumor activity in multiple solid tumor models, including prostate, ovarian, and non-small cell lung cancer.

The research demonstrates that OP-3136 functions as a potent and selective inhibitor of lysine acetyltransferase 6 (KAT6). Dr. Gopinath S. Palanisamy will present these findings in a late-breaking poster session (LB166) on April 28, 2025, from 9:00am-12:00pm CT.

Olema Oncology (NASDAQ: OLMA) reported its Q4 and full year 2024 financial results, highlighting significant progress in its breast cancer treatment pipeline. The company ended 2024 with $434.1 million in cash and equivalents, bolstered by a $250 million equity private placement.

Key developments include the advancement of two pivotal Phase 3 trials: OPERA-01 for palazestrant monotherapy in metastatic breast cancer (top-line data expected 2026) and OPERA-02 for palazestrant with ribociclib in frontline treatment, supported by a new Novartis collaboration.

Financial results showed a net loss of $33.6 million for Q4 and $129.5 million for full-year 2024, compared to $26.8 million and $96.7 million in 2023, respectively. R&D expenses increased to $124.5 million for 2024, up from $86.1 million in 2023, reflecting expanded clinical development activities.